VJHemOnc is committed to improving our service to you

ASH 2019 | Promising results for blinatumomab in younger B-ALL at first relapsed

VJHemOnc is committed to improving our service to you

Patrick Brown

Patrick Brown, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, discusses the promising results of the phase 3 trial (AALL1331; NCT02101853) of blinatumomab for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL) in younger patients. This trial investigated blinatumomab compared with standard combination chemotherapy in children and adolescents/young adults. Blinatumomab demonstrated superior efficacy and tolerability as post-reinduction consolidation prior to HSCT, resulting in higher rates of MRD response, greater likelihood of proceeding to HSCT, and improved disease-free and overall survival. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter